ASX biotech stock Mesoblast Ltd (ASX: MSB) is among the standout performers on the ASX on Thursday.
In afternoon trade, the ASX biotech stock is up 6.3% to $2.10. While Mesoblast shares remain down 23% since the start of 2026, they have still delivered a gain of approximately 17% over the past 12 months.
So, what's driving the buying interest today?
Image source: Getty Images
Ryoncil could be a game-changer
While there hasn't been any major price-sensitive news from Mesoblast today, investors appear increasingly optimistic about the company's outlook. Growing sales, a strengthened balance sheet, and the potential of its FDA-backed pipeline may be giving the market fresh arguments to buy the biotech stock.
One of the key reasons investors remain excited about this ASX biotech stock is the commercial potential of its recently approved therapy, Ryoncil. The company believes that as sales of Ryoncil continue to grow, the treatment could eventually generate enough revenue to support earnings growth and cash flow-positive operations.
Transition into sustainable business
That would be a major achievement for a biotechnology company, given that many peers spend years relying on capital raisings and external funding to fund research and development.
Investors appear increasingly focused on the possibility that Mesoblast could transition from a development-stage biotech into a commercially sustainable business. If management can successfully scale Ryoncil sales, confidence in the company's long-term financial outlook could strengthen significantly.
For a speculative ASX biotech stock, the prospect of generating sustainable cash flow is a particularly attractive catalyst and may help explain today's share price strength.
More than a one-product story
Another factor supporting investor sentiment is the growing value of Mesoblast's broader pipeline.
While Ryoncil remains the company's flagship commercial opportunity, management has highlighted that regulatory pathways are advancing for treatments targeting heart failure and chronic lower back pain. Both represent large markets with significant long-term revenue potential.
Successful approvals in either area could dramatically expand the ASX biotech stock's commercial footprint and create additional growth engines beyond Ryoncil.
Multiple shots on goal
Importantly, investors are increasingly viewing Mesoblast as a company with multiple shots on goal rather than one dependent on a single product outcome. As its portfolio expands, the business could benefit from more diversified revenue streams, potentially reducing risk and increasing resilience over time.
The combination of a growing commercial product, advancing regulatory opportunities, and the prospect of future approvals appears to be underpinning today's strong share price performance of the ASX biotech stock.
For investors willing to accept the volatility often associated with biotech investing, Mesoblast continues to offer significant upside if its commercial and clinical milestones are achieved.
